Physician profile
Alicia Steichen
NPI 1730911942
$741.21
in general payments reported to CMS, 2019-2025
12 companies · $741 in 2025
The $741 reported for 2025 was more than what 93% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $741.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $741.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $335.95 | 2025 | Slynd, Twirla |
| Organon LLC | $69.31 | 2025 | Nexplanon |
| Biogen, INC. | $57.38 | 2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $57.21 | 2025 | |
| Hologic Sales and Service, LLC | $48.06 | 2025 | Novasure, Aptima |
| Sumitomo Pharma America, INC. | $46.23 | 2025 | Myfembree |
| Astellas Pharma US INC | $40.48 | 2025 | Veozah |
| Solventum Corporation | $23.72 | 2025 | |
| Becton, Dickinson and Company | $20.88 | 2025 | Bd Onclarity |
| Abbvie INC. | $17.82 | 2025 | |
| Millicent US INC | $17.65 | 2025 | Intrarosa, Femring |
| Mayne Pharma Commercial LLC | $6.52 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alicia Steichen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.